Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment
New England Journal of Medicine · 2024
DOI: 10.1056/nejme2402719 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Jean Rouleau. Beteiligte Einrichtung: From the Montreal Heart Institute, University of Montreal, Montreal. Hauptthemen laut MEDLINE: Heart Failure, Myocardial Infarction, Cardiovascular Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
A number of therapies that have been shown to be effective in patients with chronic heart failure, including beta-blockers, mineralocorticoid receptor antagonists, and renin–angiotensin system inhibitors, have also been shown to be beneficial in patients with evidence of left ventricular systolic dysfunction, pulmonary congestion, or both after an acute myocardial infarction. 1 However, the effectiveness of an agent in patients with chronic heart failure does not necessarily imply that the agent will be effective in patients who have had an acute myocardial infarction. For example, despite the effectiveness of sacubitril–valsartan in decreasing the risk of death from cardiovascular causes or hospitalization . . .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Montreal Heart Institute, University of Montreal, Montreal.
Zitieren
APA
Rouleau, J. (2024). Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment. New England Journal of Medicine. https://doi.org/10.1056/nejme2402719
Vancouver
Rouleau J. Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment. New England Journal of Medicine. 2024. doi:10.1056/nejme2402719
BibTeX
@article{Rouleau2024,
author = {Rouleau, Jean},
title = {Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejme2402719}
}
EUVIMED